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ABSTRACT 
Inflammatory Bowel Disease (IBD) patients, such as Crohn’s disease or ulcerative colitis suffer from chronic and re- 
lapsing intestinal inflammation that favours the development of colitis associated cancer (CAC). This inflammation is 
initiated by aberrant activations of the innate immune responses associated to intestinal barrier defects. The conven-
tional medical therapies consist to decrease the inflammatory response, which also decrease the risk of colon carcinoma 
but lead to severe side-effects. Recently, a number of animal studies have demonstrated that innate immune responses 
are attenuated by stimulation of the efferent arm of vagus nerve (VN) through its neurotransmitter acetylcholine (ACh), 
that acts on resident macrophages α7 nicotinic receptor (α7 nAChR). ACh also acts as a signalling molecule in epithet- 
lial cells through cholinergic receptors such as nAChR or muscarinic (mAChR) receptors. In the current study, we 
aimed to extend these findings to CAC prevention by treating human adenocarcinoma cell lines through targeting cho- 
linergic receptors with nicotine (which binds nAChR) and ACh (which binds both cholinergic receptors). Using HT-29 
and Caco-2 cell lines, we demonstrated that ACh-induced activation of mAChR results in cell dissociation together with 
changes in expression and localization of intestinal tight and adherens junction proteins. ACh-induced modulation of 
cell adhesion proprieties correlates with the acquisition of invasive potential. By contrast, nicotine-mediated activation 
of nAChR maintains epithelial cell organisation. ACh-released by VN stimulation (VNS) could effectively preserve 
epithelium integrity thus limiting inflammatory response and tumor development. However, attention should be paid on 
the nature of the cholinergic receptor solicited. Indeed, regarding to the protective effects of nAChR signalling on 
epithelial cells, activation of mAChR would worsen the disease and led to increase inflammation. These data have im- 
portant repercussions on the therapeutic potential of VNS in IBD and CAC, which may represent “the yin and yang” of 
the intestinal homeostasis. 
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1. Introduction 
Inflammatory Bowel Diseases (IBD), such as Crohn’s 
disease (CD) or ulcerative colitis (UC), are multifactorial 
chronic inflammatory diseases of the gastrointestinal 
tract for which the exact causative mechanism is still 
unclear. According to a current hypothesis, an increased 
intestinal permeability due to an epithelial barrier defect, 
coupled with a dysfunctional immune response partici- 
pate to the development of chronic intestinal inflamma- 
tion [1]. 
In the long-term, IBD can induce further complication 
and patients have an increased risk developing other pa- 
thologies such as colorectal cancer (CRC). About 20% of 
CRC cases can be genetically attributed to a family his- 
tory. Involvement and mechanisms by which environ- 
mental factors contribute to the disease are still unclear. 
Colitis associated cancer (CAC) is a type of colon cancer 
which is preceded by clinically detectable IBD. CAC 
develops from dysplasia, which is stimulated by chronic 
inflammation, rather than polyps. Even though CRC does 
not always develop after IBD, its high frequency in pa- 
tients with IBD represents a paradigm for the connection *Corresponding author. 
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between inflammation and cancer in terms of epidemic- 
ology and mechanistic studies in preclinical models (for 
review [2]). UC increases cumulative risk of CRC by up 
to 18% - 20%, while CD by up to 8% after 30 years of 
active disease. The increase in prevalence of CAC in 
IBD patients seems to correlate with the chronic inflame- 
matory conditions of the intestinal mucosa, in particular 
with the degree [3], duration [4,5] and anatomical extent 
of colonic inflammation [6], as well as the presence of 
primary sclerosing cholangitis, and IBD management 
such as efficacy of anti-inflammatory therapies [7]. In 
animal models, intraperitoneal injection of the carcino- 
gen azoxymethane (AOM) followed by repeated cycles 
of dextran sulfate sodium (DSS) or mice lacking the gene 
for the IL-10 cytokine, chronic inflammation also results 
in an increased frequency of intestinal tumors [8,9]. Epi- 
demiological studies report that the long-term admini-
stration of anti-inflammatory drugs decreases the risk of 
colon carcinoma [10]. The conventional medical therapy 
for IBD consists to reduce the inflammatory response 
using 5-aminosalicylates, corticosteroids, immunosup- 
pressives (azathioprine/mercaptopurine), and biological 
therapies (anti-TNFα, but these treatments have severe 
side-effects [11,12]. 
Vagus nerve (VN) is the main nerve of the parasym- 
pathic division of the autonomic nervous system for the 
thoracic and abdomino-pelvic viscera that controls heart 
rate, hormone secretion and gastrointestinal motility/se- 
cretion [13]. Recent studies indicate that VN is also an 
immunomodulator [14]. In experimental models of in- 
flammatory disease, vagus nerve stimulation (VNS) at- 
tenuates the production of pro-inflammatory cytokines 
and inhibits the inflammatory process [15,16]. The in- 
flammatory reflex is a centrally neuro-endocrine-immune 
integrated physiological mechanism that maintains ho- 
meostasis through: 1) the activation of the hypothalamic 
pituitary adrenal axis by VN afferent fibers and 2) the 
cholinergic anti-inflammatory pathway (CAP) by VN 
efferent fibers [17,18]. At the molecular level, the CAP 
relies on the effects of acethylcholine (ACh), the VN 
principal neurotransmitter, on macrophages [18]. ACh 
signals through either muscarinic (G-protein-coupled) 
receptors (mAChR) or nicotinic (ligand-gated ion chan- 
nels receptors (nAChR) [19]. There are five subtypes of 
mAChR (M1-M3) which are products of distinct genes 
[20]. They present similar structure constituted of seven 
transmembrane helice (TM1-TM7) and three extracellu- 
lar and three intracellular loops [21]. nAChRs are trans- 
membrane proteins composed of five subunits arranged 
around an axis perpendicular to the membrane. Therefore, 
nAChR is a homo-(α7 or α9) or a hetero-pentamer com-
posed from various subunits (α2 - α10; β2 - β4, , , ). 
These cholinergic receptors are present in the central and 
peripheral nervous systems, in immunocompetent cells 
(monocyte, lymphocyte, and macrophage). Activation of 
α7 nAChR, either directly through interaction with selec- 
tive nicotinic agonist (such as nicotine) or indirectly 
through the activation of the autonomic nervous systems 
(e.g. VN), inhibits adaptive and innate immune responses 
[22-24]. The affinity of nicotine for this receptor is 
greater than its physiological agonist, ACh [25]. nAChR 
signaling also reduces macrophage cytokine production 
and inflammation in animal models of pancreatitis [26], 
DSS-induced colitis [27], 2,4,6-trinitrobenzene sulfonic 
acid (TNBS)-induced colitis [28] and intestinal ileus [29]. 
Thus, VNS appears as an alternative therapy to conven-
tional treatment, for digestive disorders such as IBD. 
Currently, VNS is used in treatment of patient with sei- 
zure disorders and depression through the stimulation of 
VN afferent fibers [30] or metabolism disorders such as 
obesity (for review [31]). 
Inflammation could contribute to carcinogenesis by 
increasing the level of reactive oxygen species that have 
a mutagenic effect on DNA (tumor initiation) [32] or by 
generating an environment in favour of sustained growth, 
angiogenesis, migration and invasion of tumor cells (tu- 
mor progression and metastasis). Various components of 
the inflammatory environment in IBD are key elements 
in the different steps of cancer [33]. Recent works have 
elucidated the role of various immune cells and media- 
tors in all the steps of colon carcinogenesis with the dis- 
section of some molecular pathways [2,34,35]. In this 
paper, we will focus on the therapeutic potential of VNS 
in CAC, not only by regulating inflammatory response at 
the immune level but also by preventing or limiting in- 
testinal barrier breakdown associated to the inflammation 
process. Indeed, epithelial cells also express cholinergic 
receptors [36]. While the role of α7 nAChR in intestinal 
cells is less understood, cholinergic receptors regulate 
ion transport across cell membrane and thereby affect 
intestinal water movement [37]. The main subtype of 
mAChR in rat and human intestinal epithelial cells is the 
M3 and to a lesser extends the M1 receptor [38-40]. 
Epithelia form a barrier constituted of specialized cells 
characterized by structural features including polarized 
morphology and cell-cell contacts. They lie on a base- 
ment membrane, which is organized into a complex 
structure containing collagen type IV (COIV), various 
laminin isoforms, and proteoglycans [41-43]. Interactions 
between cells and this specialized extracellular matrix 
(ECM) are crucial for essential biological processes such 
as migration, proliferation, differentiation, and cell sur- 
vival. The cell-cell or cell-ECM interactions are medi- 
ated through various transmembrane receptors, which are 
linked intracellularly to cytoskeleton components and 
signal transduction molecules [44,45]. Tight junctions 
(TJ) are composed of transmembrane proteins (claudins, 
occludins and junctional adhesion molecules), scaffold 
proteins like zona occludens (ZOs) that link the actin 
cytoskeleton, and intracellular regulatory molecules in- 
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cluding kinases [46]. Directly beneath TJ are the adher- 
ens junctions (AJ) with E-cadherin connected to the actin 
cytoskeleton via α/β catenins and regulated by p120ctn 
[47]. Disorganization of these cellular junctions could 
participate in the infection process but also in the cellular 
dedifferentiation preceding carcinogenesis and cell mi- 
gration [48]. These epithelial alterations are more pro- 
nounced in UC tissues in which the development of ma- 
lignancies is apparently more frequent than in CD tissues, 
suggesting that disturbances of junction-associated mole- 
cules are likely to be involved in carcinogenesis from 
IBD patients. Using HT-29 and Caco-2 cells, two human 
colonic adenocarcimoma cell lines, we demonstrated that 
VNS could preserve epithelium integrity thus limiting 
inflammatory response and tumor development. How- 
ever, attention should be paid on the nature of the cho- 
linergic receptor solicited. Indeed, regarding to the pro- 
tective effects of nicotine-induced activation of nAChR 
on epithelial cells, mAChR activation by ACh favours 
the acquisition of invasive potential with a modulation of 
cell adhesion proprieties. These data have important re- 
percussions on the therapeutic potential of VNS in IBD 
and CAC. 
2. Materials and Methods  
2.1. Cell Culture 
The human colon adenocarcinoma cell lines HT-29 and 
Caco-2/TC7 were cultured at 37˚C in a 5% CO2 atmos- 
phere in DMEM containing 25 mM glucose (Invitrogen, 
Cergy Pontoise, France) and supplemented with 10% 
FCS, 5% penicillin and streptomycin. The medium was 
changed every day to avoid glucose exhaustion, which 
leads to differentiation. The differentiation of HT-29 
cells was initiated by replacing standard medium by glu- 
cose free DMEM (Invitrogen) supplemented with 10% 
dialyzed foetal calf serum, 5 mM galactose, 15 mM 
HEPES, selenous acid (10−2 g/ml), penicillin, and stre- 
ptomycin [49]. This medium (Gal-medium or differenti- 
ating medium) was changed every day. The differentia-
tion of Caco-2 occurs after 15 days of culture postcon-
fluence. The cells were harvested in phosphate-buffered 
saline (PBS) supplemented with 1 mM EDTA and 0.05% 
trypsin (w/v). 
2.2. Chemical Reagents and Antibodies  
Polyclonal antibodies directed against M3 mAChR (Cat. 
N˚. AB41169) provided from Abcam (12964, Abcam, 
Paris, France). Anti-human E-cadherin (Clone HECD1) 
monoclonal antibody was obtained from Takara Bio- 
chemicals (Cambrex Bio Science, Paris, France). Mono- 
clonal antibody against p120ctn (clone 98) was pur- 
chased from BD Biosciences/Transduction Laboratories 
(Pont de Claix, France). Anti-actin (Cat. N˚. A2066), and 
anti-β catenin (Cat. N˚. C2206) polyclonal antibodies and 7 nAChR (clone 306) monoclonal antibody were ob- 
tained from Sigma Aldrich (L’Isle d’Abeau, France). 
Polyclonal antibody directed against Src-PTyr418 (AT- 
7135) was purchased from MBL Calbiochem (VWR In- 
ternational, Fontenay-sous-Bois, France), monoclonal 
anti-Src (Clone GD11) was from Millipore (Molsheim, 
France). Occludine clone (OC-3F10) and ZO-1(clone 
ZO1-1412) monoclonal antibodies were from Invitrogen 
(Cergy Pontoise, France). Alexa-conjugated goat anti- 
mouse secondary antibody was obtained from Molecular 
Probes (Eugene, OR). Horse Radish Peroxydase-conju- 
gated goat anti-mouse was from Bio-Rad (Marnes-la-Co- 
quette, France), donkey anti-rabbit antibodies were from 
Jackson Immunoresearch (Immunotech, Marseille, France). 
2.3. RT-PCR 
Total RNA extractions were performed using TrizolTM 
reagent and 1 µg of total RNA was denaturized and sub-
sequently processed for reverse transcription using M- 
MLV (Invitrogen) according to manufacturer’s instruc- 
tions and run on thermocycler (Eppendorf). Primer se- 
quences and probes are: 
 
5’CAGGGGTGAAGACTGTTCGT 
7 nAChR  
3’CACTGTGAAGGTGACATCCG 
5’CCTTCAAGGAAGCCACTCTG 
M3AChR 
3’GTCTGTGGGTTGATGTGTGC 
5’GAACATCATCCCTGGCTCTACTGG 
GAPDH 
3’AATGCCAGCCCCAGCGTCTACTGG 
 
PCR conditions are: 5 min at 92˚C followed by 35 cy- 
cles (40 sec at 92˚C, 40 sec at 60˚C and 1 min at 72˚C) 
and 10 min at 72˚C. PCR were analyzed on 1.5% agarose 
gel. Quantification was performed using Image J (NIH 
software). GAPDH were used as housekeeping gene.  
2.4. Immunoblot  
Cells were grown to confluence and lysed with a buffer 
made of 1% Triton X-100, 1% sodium deoxycholate, 
0.1% sodium dodecyl sulfate, and supplemented with 1 
mM PMSF, 2 g/mL aprotinin, 10 g/mL leupeptin, 10 M pepstatin, 2 mM CaCl2 and MgCl2, for 15 min on ice. 
Protein concentrations in lysates were determined using 
the copper reduction/bicinchoninic acid (BCA) assay 
(Pierce Chemical Co) according to the manufacturer’s 
instructions. Proteins (30 g in SDS- mercaptoethanol 
sample buffer) were resolved on 10% polyacrylamide 
gels, transferred into PVDF membranes (Hybond-C su- 
per; Amersham), and blocked in 5% bovine serum albu- 
min in 0.1% Tween 20 in TBS for 1 hr at room tempera- 
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ture. After overnight incubation at 4˚C with primary an- 
tibodies diluted in the blocking solution, blots were 
washed in TBS, 0.1% Tween 20 and then incubated with 
appropriate horseradish peroxidase-conjugated secondary 
antibodies (dilution of 1:10000) for 1 hr at room tem- 
perature before extensive washes. The blots were re- 
vealed by chemiluminescence (Amersham ECL reagents) 
and quantified with Image J software from NIH. Primary 
antibodies were used at the following dilutions: anti- 
human 7 nAChR and M3 mAChR, E-cadherin, p120ctn 
and -catenin (1:1000), ZO-1 (1:2000), and anti-actin 
(1:2000).  
2.5. Immunofluorescent Staining 
Cells were grown on glass coverslips and were treated as 
described previously [50]. After fixation with PFA-4% 
sucrose, non-specific sites were blocked for 1 hr at 37˚C 
with 3% BSA-0.5% Tween20. Then cells were incubated 
for 1 hr at 37˚C with specific antibodies which were di- 
luted in the blocking solution at 1:100 for primary and 
1:500 for secondary antibodies. Fluorescence photomi- 
crographs were taken with a confocal microscope at the 
x100 objective (Leica TCS SPE) or an epifluorescence 
microscope at the x100 objective (ZEISS, Avio Vert 200 
M).  
2.6. Extracellular Matrix Preparation and Cell 
Adhesion 
Tissue culture dishes were coated with LM-332 using the 
following methods: A431 epidermoid cells were cultured 
to confluence on various surfaces at 37˚C to allow for the 
deposit of LM-332, then cells were removed as previ- 
ously described [51,52]. Briefly, confluent monolayers 
were sequentially extracted with 1% (v/v) Triton X-100 
in PBS, followed by 2M urea in 1M NaCl. All extraction 
buffers contained protease inhibitors (1mM phenyl-me- 
thylsulfonyl fluoride and 2 mM N-ethylmaleimide). Plates 
were washed in PBS, incubated with 1%BSA, and stored 
at −20˚C. Human collagen type IV from placenta was 
obtained from Sigma Aldrich. Coating of plastic Petri 
dishes (Microtiter plates 96-well, Nunclone; Nunc, Ro- 
skilde, Denmark) was performed by overnight incuba- 
tion with extracellular matrix proteins (10 µg/mL) at 4˚C. 
Plates were saturated with 3% (w/v) BSA in PBS for 2 
hrs at 37˚C to block nonspecific adhesion. HT-29 cells 
were harvested and pre-treated or not with 100 nM nico- 
tine or ACh for 30 min before to be plated (5  104 cells/ 
well) in triplicate in coated 96-well microtiter plates and 
incubated from 0 to 60 min at 37˚C. Non adherent cells 
were removed by washing three times with PBS, and cell 
adhesion was estimated by a colorimetric cell prolifera- 
tion assay (CellTiter 96 AQueous Non-Radioactive Cell 
Proliferation Assay; Promega). 
2.7. Cell Invasion Assay 
Total HT-29 cells (2.5  10−5/mL) were placed in the top 
compartment of a 24-multiwell insert plate (BD Falcon), 
which was separated from the bottom compartment by 
BD-Matrigel Matrix membrane, with 0.4-µm pore size. 
Serum-free RPMI with or without nicotine or ACh (100 
nM) were added into the top compartment and 10% FCS 
into the bottom compartment. After 48 hrs at 37˚C in a 
5% CO2 atmosphere, cells that had invaded through the 
Matrigel were analyzed: cotton swabs were used to re- 
move cells on the upper surface of inserts. After fixation 
with PFA 4%, migratory cells were stained with Hema- 
toxylin Gill’s formula (Vector Laboratories) and manu- 
ally counted under the microscope. The mean values of 
the readings and their SEM were calculated, and statisti- 
cal differences were analyzed using Student’s t-test for 
non-paired samples. 
2.8. Assay for Cell Proliferation 
Cell were plated in 96-well plates (2000 cells/well) at 
day 0 and cultured in complete DMEM medium without 
or with nicotine and ACh (100 nM). Cell proliferation 
was evaluated from day 1 to 3 using the CellTiter 96 Kit 
(Promega) according to the manufacturer’s instructions. 
2.9. Densitometric Analysis and Statistics 
Immunoblots shown are representative of at least three 
independent experiments. All graphs represent the mean 
value ± SD of protein expression levels measured by 
densitometric analysis in “Image J” software (NIH). Sta- 
tistics were performed with unpaired t-test and statistical 
significance was given by the number of asterisks (*P < 
0.05; **P < 0.01; ***P < 0.001). 
3. Results  
3.1. Expression and Regulation of Cholinergic 
Receptors Expression in Human Colon  
Cancer Cell Lines 
It has been described that human colon cancer cell lines 
expressed mainly M3AChR and α4, α5, α7 and β1 
nAChR subunits but only α7 subunits form a functional 
receptor [53]. First, we analyzed whether α7 nAChR and 
M3AChR, the two major cholinergic receptors suscepti- 
ble to be activated by ACh released by VNS are present 
tors was visualized by staining HT-29 cells and then im- 
aging under confocal microscopy (Figure 1(a)). Without 
treatment, immunofluorescence staining demonstrated 
that these receptors produced varying intensities of label- 
ling in the cells, seemingly localized at the membrane. 
Some cytoplasmic dots are observed probably matching 
with cholinergic receptor neosynthesis or endocytosis. 
There is also an accumulation of vesicles enriched in α7  
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Figure 1. Functional cholinergic receptors: expression, dis- 
tribution and regulation. (a) Expression and distribution of 
functional cholinergic receptors in HT-29 cells. Confocal 
immunofluoresence analysis of α7 nAChR (green) and 
M3AChR (red) in HT-29 cells incubated (or not) with nico- 
tine or ACh (100 nM, 5 hrs). Co-localization is illustrated 
by yellow staining. Scale bar, 20 µm. (b) Cholinergic recap- 
tor expression during cell differentiation. HT-29 cells are 
differentiated during 10 days by glucose starvation. Caco-2 
cells are differentiated during 15 days after these cells 
formed a monolayer. Expressions of α7 nAChR and 
M3AChR in HT-29 cells and Caco-2 TC7 cell lines are 
quantified from immunoblot. Actin is used as loading con- 
trol. C: Influence of cell density on cholinergic receptor 
expression. HT-29 cells are seeded at different concentra- 
tion. Expression of cholinergic receptors are analysed by 
RT-PCR with specific primers. GAPDH are used as keeping 
house gene. 
 
nAChR at the extern edge of cells not engaged in cell- 
cell contacts. In presence of cholinergic ligands (nicotine 
or ACh, 100 nM, 5 hrs) we observed cell dissociation 
(black spaces appeared between adjacent cells) associ- 
ated with a modification of the cell shape (more spread- 
ing cells) in presence of ACh. Cholinergic treatment in- 
duces a hypercholinergic response (desensitization proc- 
ess) which is illustrated by a decrease of cholinergic re- 
ceptor density at the membrane of epithelial cells with a 
concomitant increase of cytoplasmic labelling which 
indicate that they receptors are functional. Then their 
expression was analyzed at the protein level and accord- 
ing to the status of differentiation of epithelial cell lines 
(Figure 1(b)). For this purpose we chose two adenocar- 
cinomas cell lines (HT-29 and Caco-2) able to differenti- 
ate in vitro under specific culture conditions. The differ- 
entiated state of HT-29 cells is obtained by substitution 
of glucose for galactose (Gal medium) in culture medium 
[54]. A variety of changes in the adhesive properties of 
HT-29 cells is observed during the first ten days of cul- 
ture in the Gal medium which corresponds to the initial 
step of their differentiation [55,56]. Enterocyte differen- 
tiation of Caco-2 cells occurs after they reached conflu- 
ence. They must be grown in confluent monolayer at 
least for 15 days [57]. Western blot also confirmed the 
presence of α7 nAChR and M3AChR in both cell lines. 
According to the differentiation status of cells, it ap- 
peared thatα7 nAChR increases during the differentia- 
tion of HT-29 cells and stays constant in Caco-2 cells. In 
contrast M3AChR expression decreases in HT-29 cells 
while it increases in Caco-2 cells. AChR expression ac-
cording to the cell density was analyzed by RT-PCR 
(Figure 1(c). α7nAChR are present at low cell density 
and their expression decreases at higher cell concentra- 
tion. In contrast the expression of M3AChR slightly in- 
creases with the cell density. These observations could 
explain the discrepancy noticed during the differentiation 
of the two cell lines. Indeed during the differentiation 
process, the substitution of glucose by galactose leads to 
cell death and thus lost of HT-29 cells. In contrast Caco- 
2 cells are still confluent.  
3.2. Only mAChR Induces a Loss and  
Redistribution of TJ and AJ Proteins 
Disruption of epithelial barrier integrity is identified as 
one of the pathologic mechanisms in IBD and cancer 
development. Adequate intestinal TJ protein function 
determines intestinal barrier integrity. We measured 
changes in expression and localization of occluding and 
ZO-1 to determine whether modulation of these TJ pro-
teins correlates with changes observed with cholinergic 
treatment [58,59]. For this purpose, we use differentiated 
Caco-2 cells which established “mature” TJ compared to 
HT-29 cells. Confluent monolayers of Caco-2 cells dif- 
ferentiated for 15 days were harvested and immunoblot- 
ted (Figure 2(a)). Western blots indicated that while 
nicotine didn’t modify the expression of ZO-1 and oc- 
cludin, ACh induces a time dependent loss of expression 
of these two TJ proteins. Fluorescence microscopy 
analysis confirmed the changes observed in western blots 
(Figure 2(b)). Membrane polarity was estimated by the 
actin cytoskeletal organization in microvilli at the apical 
side and actomyosin ring behind. In contrast to nicotine 
which preserves the actin cytoskeleton structures, ACh 
induces a reorganization of actin cytoskeleton with a loss 
of actomyosin ring and microvilli. At the same time, 
there is a redistribution of ZO-1 and to a lesser extend 
occludin from the intercellular junctions. Effect of cho- 
linergic treatment was then evaluated on subjacent AJ 
proteins (Figure 3). Similar results were obtained with 
HT-29 and Caco-2 cells. In HT-29 cells, ACh also in- 
duces a loss of E-cadherin and catenins protein expres 
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(b) 
Figure 2. Cholinergic signaling modifies TJ protein expres- 
sion and distribution. (a) Differentiated Caco-2 cells, which 
express TJ, are treated (or not) with nicotine or ACh (100 
nM) during 0 to 48 hrs. Expressions of ZO-1 and occludin 
are analyzed by immunoblotting. Actin is used as a loading 
control. B: Immunofluorescence images of actin cytoskele-
ton organization at the apical pole and TJ protein distribu-
tion in Caco-2 incubated (or not) with nicotine or ACh (100 
nM, 5 hrs). Scale bar: 20 µm. 
 
sion determined by western blots (Figure 3(a)). Confocal 
microscopy analysis showed that nicotine induces slight 
cell dissociation but E-cadherin was still at the mem- 
brane together with p120ctn/β-ctn. Both catenins were 
co-localized (Figure 3(b)). In presence of ACh, cells 
completely dissociated and E-cadherin staining was cy- 
toplasmic. Membrane labelling of catenins also disap- 
peared and less co-localization between the two proteins 
was observed.  
Localization and stability of AJ proteins were con- 
trolled by phosphorylation/dephosphorylation events. 
The kinase Src is one of the kinases involved in this 
process and it can be activated by cholinergic ligands. 
We then compared the ability of nicotine and ACh to 
activate Src by measuring its phosphorylation on tyr418 
(Figure 4). Exposure of HT-29 cells to nicotine doesn’t 
induce any Src activation during the time course experi- 
ment. By contrast Ach treatment leads to a time-depen- 
dent activation of Src with a maximum at 5 hrs. 
Altogether these data indicate that ACh but not nico- 
tine induces an alteration of epithelial cell integrity char- 
acterized by a loss of TJ and AJ proteins subsequently to 
cell dissociation and protein endocytosis and degradation. 
This phenomenon could be address by the activation of 
 
(a) 
 
(b) 
Figure 3. Cholinergic signaling modifies AJ protein expres- 
sion and distribution. (a) HT-29 cells are treated (or not) 
with nicotine or ACh (100 nM) during 0 to 48 hrs. Expres- 
sions of E-cadherin, -catenin and p120ctn are analyzed by 
immunoblotting. Actin is used as a loading control. (b) 
Confocal immunofluorescence images of AJ proteins. HT- 
29 cells which express AJ are incubated (or not) with nico-
tine or ACh (100 nM, 5 hrs. Upper panel: E-cadherin 
(green), lower panel: p120ctn (green), β-ctn (red). Co-lo- 
calization of p120ctn and β-catenin is illustrated by yellow 
staining. Scale bar: 20 µm. 
 
 
Figure 4. Src-phosphorylation following AChR activation. 
Westernblots showing Src-pTyr418 and Src total expression 
following nicotine and ACh treatment (100 nM) during 0 to 
24 hrs in HT-29 cells. 
 
the Src kinase.  
3.3. ACh Modifies Cell-ECM Adhesion and 
Stimulates Human Cancer Cell Invasion 
The AJ’s disassembly correlates with a loss of cell-cell 
adhesion and an acquisition of  migratory potential [60]. 
This event is associated to a modification of cell-ECM 
adhesive properties. We then compared the adhesive po- 
tential of HT-29 cells treated or not with cholinergic re-
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ceptors on collagen IV (COIV) and laminin-332 (LN- 
332), two major proteins of the basal membrane (Figure 
5(a)). Nicotinic treatment enhances cell adhesion to 
COIV and had no effect on LN-332. By contrast, expo- 
sure of HT-29 cells to ACh diminishes adhesion to both 
ECM proteins. These modifications of ACh-induced cell- 
ECM interactions were correlated to an enhanced capac- 
ity of HT-29 cell invasion (Figure 5(b)). Using Matrigel 
chamber assays, we found that ACh induced a 3-fold 
increase in HT-29 cell invasion. Nicotine had no effect 
on HT-29 cell invasion. These results indicate that acti- 
vation of mAChR by ACh modifies cell adhesive pro- 
prieties in favour of invasion.  
3.4. Ach Enhances Cell Proliferation 
ACh is an autocrine/paracrine factor in various non neu- 
ronal cells. Consistent with previous observations, we 
found that ACh reproducibly induced a 1.7-fold increase 
in HT-29 cell proliferation at 48 hrs and 72 hrs after 
seeding (Figure 6). Nicotine also significantly stimulated 
HT-29 cell proliferation (1.3-fold increase). 
In this present work, data indicate that ACh-induced 
mAChR signaling plays a key role in colon cancer cell 
polarity and adhesion, proliferation and invasion com- 
pared to nAChR.  
4. Discussion 
IBD patients suffer from chronic and relapsing intestinal 
inflammation that favours the development of CAC. This 
 
 
(a)                          (b) 
Figure 5. Cholinergic signaling modulates migration and 
invasion potential in HT-29 cells. (a) Contrary to mAChR 
signaling, nAChR activation promotes cell adhesion. HT-29 
cells are treated (or not) with nicotine or ACh (100 nM, 5 
hrs) 30 min before adhesion and then plated on either type 
IV collagen (COIV) or laminin-332 (LN-332) at 10 µg/mL. 
Cell adhesion is evaluated using a Cell Titer Aqueous MTT 
reagent kit. Results are expressed relative to the untreated 
cells which are fixed at 1. Data represent the mean +/- SEM 
of 4 experiments. (b) Contrary to nAChR signaling, mAChR 
activation favors cell migration. Effect of nicotine and ACh 
(100 nM, 48 hrs) on HT-29 cell transmigration is deter-
mined using a transwell assay. Cells which migrated through 
the matrigel are stained with hematoxylin and visualized 
and counted by phase contrast microscopy. Results are ex- 
pressed according to the control which is fixed at 1. Data (n 
> 3) represent the mean +/− SEM.p 
inflammation is initiated by aberrant activations of the 
innate immune responses associated to intestinal barrier 
defects. Recently, a number of animal studies have dem- 
onstrated that innate immune responses are attenuated by 
stimulation of the efferent arm of VN through its neuron- 
transmitter ACh, that acts on resident macrophages 7 
nAChR, [15,16]. It appeared that ACh is not only a neu- 
rotransmitter but it also acts as a signaling molecule in 
non-neuronal tissues. In the current study, we aimed to 
extend these findings to CAC prevention by treating hu- 
man adenocarcinoma cell lines through targeting cho- 
linergic receptors with nicotine and ACh. nAChRs and 
mAChRs might affect the inflammatory response in an 
opposite manner and may represent “the yin and yang” of 
the intestinal homeostasis [61]. Our data suggest that 
nAChR and mAChR might also affect differently cancer 
progression (Figure 7). 
 
 
Figure 6. Cholinergic signaling modulates HT-29 cell pro- 
liferation. To determine proliferation potential, HT-29 cells 
are incubated (or not) with nicotine or ACh (100 nM) dur- 
ing 24, 48 and 72 hrs. Cell proliferation is determined by 
MTT assays. Results are expressed relative to the prolifera- 
tion of untreated cells, which is fixed at 1. Data represent 
the mean +/− SEM of 3 experiments. 
 
 
Figure 7. “The ying and the yang” effect of VNS. In IBD 
patients, VNS would have protective effects on epithelial 
barrier integrity via nAChR. This effect relies on a positive 
modulation of intercellular junction proteins in term of 
expression and localization. In an opposite manner, VNS- 
mediated activation of mAChR leads to cell-cell contact 
disruption with intercellular junction proteins degradation 
and delocalization together with a decrease of cell-ECM 
adhesion. Altogether these effects favor cell migration and 
invasion as observed in tumor progression. 
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4.1. Acetylcholine, Neurotransmitter and 
Autocrine/Paracrine Mediator 
Emerging evidences indicate that normal and neoplastic 
non-neuronal cells can produce and release ACh in suffi- 
cient quantity to modulate cell function [62]. Neuronal 
and non-neuronal (epithelial, endothelial and immune 
cells) ACh is synthesized by the enzyme choline acetyl- 
transferase (ChAT) using acetyl-CoA and choline as 
substrates. The later is taken up from the extracellular 
site by a specific high affinity choline transport-system 
(CHT1) [62,63]. In contrast to the situation in nerves 
where ACh is stored in specific vesicles, there is no 
storage compartment in non-neuronal cells and ACh ap- 
peared to be released directly after synthesis. In both 
conditions, ACh is rapidly hydrolysed by acetylcholi- 
nesterase (AChE), thereby limiting its action to immedi- 
ately neighbouring cells. ACh targets mAChR and nACR 
with a greater affinity for the former. Both receptors are 
widely expressed in different non-neuronal cell types (for 
review [64,65]. Different mAChRs couple differentially 
to multiple G proteins that are describe to mediate dis- 
tinct cytoplasmic signaling pathways implicated in vari- 
ous cellular functions. Activation of nAChR leads to 
Ca
2+ influx that directly modulates these signaling path- 
ways. 
4.2. Regulation of the Cholinergic System in 
Cancer  
All components of the cholinergic system such as syn- 
thesis, storage, release, inactivation as well as the ex- 
pression and function of various cholinergic receptors 
can be affected in pathophysiological conditions. Some 
substantial alterations of the non-neuronal cholinergic 
system have already described in human colon cancers. 
The cholinergic system for ACh synthesis and degrada- 
tion is modified in human colon cancer cell lines com- 
pared to normal tissues. The activity of AChE was meas- 
ured in 55 human samples of healthy and malignant co- 
lon, sigmoid colon and rectum. It appeared that cancer 
decreases the average of AChE activity value, such in- 
creasing the rate of ACh [66]. Moreover, Cheng and col- 
leagues demonstrated that ChAT staining is undetectable 
to weak in normal enterocytes but is moderate to strong 
in 50% of colon cancer examined and colon cancer cell 
lines [67]. This data show that colon cancer cells possess 
the ability to produce and release ACh, which could act 
as an autocrine/paracrine factor. While there is few data 
on the regulation of ACh release during inflammation, it 
has been shown that corticoids negatively modulate the 
non-neuronal cholinergic system by regulating transport 
and synthesis of ACh in particular at the surface epithet- 
lium of trachea and intestine [68]. 
In gastrointestinal tissue, the primary mAChR subunits 
are M1AChR, M2AChR and M3AChR, but colon 
epithelial cells mainly express M1AChR and M3AChR 
[38-40,69]. Frutcht et al. reported that human colon can- 
cer cell lines and colon cancer tissues express M3AChR. 
Their expression is increased up to 8-fold in cancer 
compared to normal tissue [70]. This over-ex- pression is 
observed in 60% of colon cancer examined [71]. The 
over-expression of M3AChR is associated to a drop of 
degradation and an increasing of ACh synthesis. Corti- 
coids also modulate the expression of mAChR, in a cell 
specific manner: glucocorticoids decrease M2AChR and 
M3AChR density in airway smooth muscles [72] while 
they up-regulated M2AChR in parasympathic nerves 
[73]. 
Since the discovery of ubiquitous presence of nAChR 
in mammalian cells, studies from many laboratories have 
linked nAChR with various pathological conditions in-
cluding cancer [74]. These studies were performed with 
nicotine and concern tobacco-related carcinogenesis such 
as lung cancer. However it is clear that various nAChR 
subtypes are expressed in non-neuronal cells but their 
pattern of expression and their functional roles is under 
debate [65,75]. nAChRs are expressed in various human 
cancers with subunit expression altered except the 7-subunit, which is constantly expressed and functional 
(reviewed in cardinale et al., 2012). It has been proposed 
that looking at the differentiation status of the tumor, 
there is a tendency of a major expression of α7 nAChR 
protein levels in more differentiated human lung tumors 
[76]. We found that the M3AChR and α7 nAChR are 
expressed in HT-29 and Caco-2. Their expression is not 
correlated to the differentiation status of these cell lines 
but rather to the cellular density. This result was con- 
firmed using various human colonic cell lines character- 
ized by different stage of differentiation (data not 
shown).  
4.3. How mAChR May Participate in CAC? 
Muscarinic receptor activation stimulates proliferation, 
migration and invasion of human colon cancer cells 
[77-79]. These effects have been attributed to M3AChR- 
induced secretion of matrix metalloprteinases (MMPs) 
such as MMP7 that releases EGF ligands or MMP1. 
Most of M3AChR effects seem to be mediated by trans- 
activation of the EGFR. Co-expression of M3AChR and 
EGFR in many colon cancer cell lines associated with 
over expression of these receptors in the majority of co- 
lon cancer suggests that the functional interaction be- 
tween M3AChR and EGFR is important for colon cancer 
regulation. In human colon cancer cell lines, we found 
that ACh alters the assembly of intercellular junctions 
(AJ and TJ), a process associated to epithelial barrier 
failure. This correlates with the observation that mAChR 
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(in particular M3) increases epithelial cell permeability 
[80]. This ACh–induced alteration of cellular contacts, 
decreases cell-ECM adhesion and stimulates invasion of 
HT-29 cells. Recent research demonstrated that the mo- 
lecular mechanism of cholinergic control of keratinocyte 
adhesion involves an ACh receptor-dependant changes in 
the phosphorylation status of adhesion [81,82]. The ph- 
osphorylation of adhesion molecules plays an important 
role in assembly/disassembly of intercellular junctions 
controlling their structural integrity and the adhesive ca- 
pacity [83-86]. Tyrosine phosphorylation of p120ctn or 
serine phosphorylation of α-ctn correlate with a decrease 
of cell adhesion and represent the initial event for their 
degradation [87,88]. The phosphorylation status of a 
given adhesion molecule is determined by both protein 
kinase and phosphatase activities. Various kinases have 
been described to phosphorylate proteins among which 
the Src kinase [89,90]. We found that ACh but not nico- 
tine induces Src phosphorylation on Tyr 418.  
Strong evidences for non-neuronal ACh production are 
reported in human keratinocytes and small lung cancer 
cells where this transmitter acts as an autocrine/paracrine 
growth factor stimulating cell proliferation [91,92]. Si- 
milarly, ACh produced and released by H508 colon can- 
cer cells interacts with M3AChR and acts as an autocrine 
growth factor [93]. In HT-29 cells, we found that ACh 
also stimulates cell proliferation. An increasing number 
of evidences suggests that cyclooxygenase-2 (Cox-2) ex- 
pression is associated with colon cancer induction and 
progression by stimulating cell proliferation, suppressing 
apoptosis, inducing tumor angiogenesis and promoting 
invasiveness [93]. However, M3AChR and Cox-2 share 
the same signaling cascade. M3AChR activation is cou- 
pled to the phospholipase C (PLC) signaling cascade and 
PLC-activated protein PKC is an inducer of Cox-2. In 
HT-29 cells, Yang and Frucht showed that stimulation of 
M3AChR by carbachol up-regulates COX-2 protein ex- 
pression in a concentration and time- dependent manner 
[71]. So, Cox-2 could constitute the molecular bridge be- 
tween inflammation and cancer, and mediate in part the 
effect of M3AChR.  
Together, these finding indicate that M3AChR expres- 
sion plays a strong role in intestinal tumor promotion by 
modulating key process of carcinogenesis. Using differ- 
ent in vivo models, Raufman et al., showed that M3AChR 
gene ablation decreases both colon tumor number and 
size and the degree of dysplasia [94]. Indeed, only low- 
grade adenomas are detected from Apc
min/+ M3AChR−/− 
mice while in Apcmin/+ M3AChR+/+ mice both low and 
high grade adenomas are observed [95]. Furthermore, 
M3AChR selective inhibitors have been proven to re- 
duced the size of small cell lung cancer xenografts in 
nude mice [96] suggesting that M3AChR are key pro- 
moters of tumor growth. 
4.4. Protective Effects of nAChR 
As mAChR, nAChR have been described to modulate 
epithelial cell-cell contacts, adhesion and motility of res- 
piratory epithelial cells, lung cancer and in a variety of 
human cancer cell lines [97-99]. Nicotine can induce the 
transition from a well-differentiated epithelial cell to a 
highly invasive carcinoma cell involving different sig- 
nal transduction cascades. Long-term treatment of lung 
cancer and breast cancer cells is required for these effects. 
In these models it has been proposed that nicotine, acting 
via α7 nAChR, stimulates mRNA and protein expression 
of fibronectin with a concomitant down regulation of 
junctional protein expression and/or localisation [98,100, 
101]. Evidence of nAChR mediated activation of inte- 
grin-dependent signaling pathway has also been obtained 
in colon and gastric cancer [102]. Regarding the gastro- 
intestinal tract, Cho’s laboratory showed that nicotine 
induced activation of α7 nAChR and stimulated the 
growth and angiogenesis of gastric and colon cancer by 
systemic as well as cellular increase in stress neuro- 
transmitters (adrenaline, noradrenaline) leading to β-ad- 
renergic signaling, transactivation of the EGFR and re- 
lease of EGF [103-105].These finding strengthen the 
hypothesis that modulation of nAChR upon chronic ex- 
position to tobacco may contribute to the development 
and progression of cancer. 
However in some cases, nicotine and tobacco could 
exert protective effects. UC patients with a history of 
smocking usually developed their disease after they had 
stopped smocking [106-108]. Smoking has been found to 
reduce development and severity of UC and to worsen 
the disease in CD patients [106,109,110]. Similarly, nico- 
tine administration ameliorates disease in DSS experi- 
mental colitis [111]; while worsened the course in TNBS 
colitis [112]. In patients, [113] treatment with transder- 
mal nicotine was effective at inducing disease remission 
in UC patients but patients suffered from adverse effects 
[114]. Thus the effects of nicotine and 7 nAChR ago- 
nists may depend on many factors such as disease model 
and severity, the expression and the subtype of nAChRs. 
According to these data and our observations, it appeared 
that cholinergic receptor expression must be determined 
before VNS therapy. 
Using a concentration similar to those observed in the 
blood of smokers (0.01 - 1 M), we found that nico- 
tine-mediated activation of α7 nAChR exert protective 
effect on epithelial morphology that can preserve from 
failure of barrier function. Nicotine increased or main- 
tained the expression of various intercellular proteins 
such as p120ctn, Z0-1, Occludin. This mechanism may 
contribute to maintain barrier integrity. McGilligan has 
described similar results, showing that nicotine decrease 
Caco-2 permeability by regulating the expression of TJ 
proteins [115]. This process is important to reduce in- 
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flammation but also cancer progression. In a rodent 
model of intestinal inflammation after severe burn injury, 
Costantini and collaborators showed that nicotine ad- 
ministration prevent burn-induced intestinal permeability 
and limited histological injury by controlling intercellular 
protein expression and localisation [116]. These effects 
could also be mediated by VNS of enteric nervous sys- 
tem [117]. 
Many mechanisms are responsible for the up-regula- 
tion of junction proteins by nicotine. One possibility is 
the activation of extracellular signal related kinase (ERK) 
or mitogen activated kinase (MAPK). Nicotine is de- 
scribed to increase the expression of these kinases [118, 
119]. Another possibility is a nicotine-mediated decrease 
of the nuclear factor kappa B (NFkB). This factor has 
been described to regulate TJ permeability [120,121] and 
Cox-2 expression [122,123], a CRC tumor promoting 
factor [93]. Finally, α7 nAChR activation can regulate 
the stability of the junction proteins by controlling their 
phosphorylation status. Indeed, in keratinocytes, Chern- 
yavsky et al., showed that α7 nAChR activates adhesion 
molecules by both inhibiting Src family kinases and ac-
tivating protein tyrosine phosphatases (PTP) [124]. nAChRs 
can be associated with both Src and PTP in large mul- 
timeric complexes controlling their activation [125]. 
Recently, nAChR has been implicated in regulating 
the release of the neurotransmitter -aminobuturic acid 
(GABA), which may act as a tumor suppressor in par- 
ticular, in colon carcinoma and lung adenocarcinoma 
cells [126,127]. The heterotrimeric α42 nAChR, which 
binds ACh and nicotine with higher affinity than α7 
nAChR, stimulates the release of GABA. This higher 
affinity for nicotine is thought to cause the long-term 
inactivation (or desensitization) of the heteromeric nAChR 
that has been observed after chronic exposition to nico- 
tine such as smokers. By contrast the sensibility of α7 
nAChr remains unchanged, its expression is up-regulated 
by nicotine and its biological effect is increased [128]. 
The effect induced by nicotine may be different in 
various cell types, differentiated or “totipotent”, and 
having diverse metabolic properties to convert nicotine in 
its metabolite such as cotinine which is more toxic. More- 
over, these effects may be related to different factors 
such as: 1) length of exposure (short versus chronic); 2) 
concentration (high or low); 3) anatomical distribution 
and expression of receptor subtypes. Finally, the α7 nAChR 
effects could be modulated by the secreted mammalian 
LY-6/urokinase plasminogen activator receptor-related 
protein-1 (SLURP-1) that has been recently identified by 
an endogenous ligand for α7 nAChR which exerts pro- 
tective effect [59].  
4.5. Potential Therapeutic Use of VNS 
To date different approaches have been done targeting 
nAChR in cancer therapy in particular tobacco-related 
carcinogenesis. In this case, the challenge is to develop 
compound capable of inhibiting α7 nAChR or potentiat- 
ing α42 nAChR to counterbalance the deleterious ef- 
fects of chronic nicotine (for review [129]. Most promis- 
ing compounds have side-effects in particular on the cen- 
tral nervous system since they can cross the blood-brain 
barrier. In improving the strategy for treating IBD pa- 
tients, VNS could represent an attractive therapeutic ap- 
proach to prevent CAC. VNS (afferent fibers) at high 
frequency (30 Hz) is already successfully used in humans 
in the treatment of depression, seizure and more recently 
metabolism troubles [30,31]. Now this technique could 
be extended to gastrointestinal disorders such as IBD 
using a low frequency stimulation (5 - 10 Hz) which is 
known to activate efferent fibers (for review [12]). In this 
condition, VNS uses a physiological anti-inflammatory 
pathway and represents a safe technique with even less 
side-effects. A reduction of inflammation is a key step 
for decrease the risk of CAC. However we should keep 
in mind that the nature and the subtype of cholinergic 
receptors on target cells should be carefully investigated 
before evaluating the effectiveness of nAChR as a drug 
target in these patients. Indeed, stimulation of mAChR 
play key role in colon cancer cell invasion.  
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